EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOSIG00000023118
Gene Symbol: MAP3K12
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOSIG00000023220
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSOSIG00000016340
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSOSIG00000017386
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOSIG00000002370
Gene Symbol: MAP3K8
1 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSOSIG00000019741
Gene Symbol: MAP3K9
1 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSOSIG00000004174
Gene Symbol: MGLL
1 Cross references
207 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSOSIG00000023874
Gene Symbol: MLNR
1 Cross references
174 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSOSIG00000000085
Gene Symbol: NPR1A
1 Cross references
190 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSOSIG00000006315
Gene Symbol: NPR3
1 Cross references
211 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSOSIG00000003567
Gene Symbol: NPY2R
1 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSOSIG00000010483
Gene Symbol: NPY2R
1 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).